Literature DB >> 25806299

Focus on treatment complications and optimal management: radiation oncology.

Charlotte Billiet1, Stephanie Peeters1, Dirk De Ruysscher1.   

Abstract

BACKGROUND: Esophagitis and pneumonitis are the most important treatment complications and dose-limiting toxicities in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) alone or combined modality therapy.
METHODS: A literature research was performed to identify published articles relating clinical and dosimetric parameters associated with significant radiation pneumonitis (RP) and esophagitis in NSCLC patients treated with three-dimensional conformal RT.
RESULTS: Possible clinical parameters associated with acute and or late esophagitis are concurrent chemoradiation, hyperfractionated and accelerated radiation regimens, dysphagia and neutropenia during treatment. Mean dose <34 Gy is currently used as standard dosimetric recommendation. Addition of chemotherapy and hyperfractionation are also associated with the risk of pneumonitis. Both the V20 and the mean lung dose are used as dosimetric parameter to correlate with the risk of high-grade radiation pneumonitis.
CONCLUSIONS: A variety of clinical and dosimetric parameters have been associated with acute and late toxicity. Treatment consist mainly in symptomatic relieve. Further research is necessary, as many studies led to different and sometimes even contradictory results.

Entities:  

Keywords:  Pneumonitis; esophagitis; radiotherapy (RT); toxicity

Year:  2014        PMID: 25806299      PMCID: PMC4367685          DOI: 10.3978/j.issn.2218-6751.2014.06.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  29 in total

Review 1.  Biology of oral mucosa and esophagus.

Authors:  C A Squier; M J Kremer
Journal:  J Natl Cancer Inst Monogr       Date:  2001

Review 2.  European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer.

Authors:  Dirk De Ruysscher; Corinne Faivre-Finn; Ursula Nestle; Coen W Hurkmans; Cécile Le Péchoux; Allan Price; Suresh Senan
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

3.  The opossum as an animal model for studying radiation esophagitis.

Authors:  M G Northway; H I Libshitz; J J West; H R Withers; A K Mukhopadhyay; B M Osborne; I A Szwarc; G D Dodd
Journal:  Radiology       Date:  1979-06       Impact factor: 11.105

4.  Repopulation in mouse oral mucosa: treatment splits.

Authors:  W Dörr
Journal:  Radiother Oncol       Date:  1994-11       Impact factor: 6.280

5.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).

Authors:  Shulian Wang; Zhongxing Liao; Xiong Wei; Helen H Liu; Susan L Tucker; Chao-Su Hu; Rodhe Mohan; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-25       Impact factor: 7.038

6.  Intraosseous venography with carbon dioxide contrast agent in percutaneous vertebroplasty.

Authors:  Noboru Tanigawa; Atsushi Komemushi; Shuji Kariya; Hiroyuki Kojima; Satoshi Sawada
Journal:  AJR Am J Roentgenol       Date:  2005-02       Impact factor: 3.959

7.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

Authors:  P D Maguire; G S Sibley; S M Zhou; T A Jamieson; K L Light; P A Antoine; J E Herndon; M S Anscher; L B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

8.  A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.

Authors:  J D Cox; N Azarnia; R W Byhardt; K H Shin; B Emami; T F Pajak
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

9.  Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.

Authors:  M Werner-Wasik; C Scott; M L Graham; C Smith; R W Byhardt; M Roach; E J Andras
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-05-01       Impact factor: 7.038

10.  The importance of patient characteristics for the prediction of radiation-induced lung toxicity.

Authors:  Cary Dehing-Oberije; Dirk De Ruysscher; Angela van Baardwijk; Shipeng Yu; Bharat Rao; Philippe Lambin
Journal:  Radiother Oncol       Date:  2009-01-13       Impact factor: 6.280

View more
  2 in total

1.  Model Calibration of Pharmacokinetic-Pharmacodynamic Lung Tumour Dynamics for Anticancer Therapies.

Authors:  Maria Ghita; Charlotte Billiet; Dana Copot; Dirk Verellen; Clara Mihaela Ionescu
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

Review 2.  Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects.

Authors:  Anup Kainthola; Teena Haritwal; Mrinialini Tiwari; Noopur Gupta; Suhel Parvez; Manisha Tiwari; Hrideysh Prakash; Paban K Agrawala
Journal:  Front Immunol       Date:  2017-05-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.